United States Patent 5,785,053: Claim Scope, Expiration, and IUD Inserter Patent Landscape

U.S. Patent No. 5,785,053 covers a mechanical inserter for a T-shaped intrauterine device, particularly an IUD with folding transverse wings, a plunger, a sliding protective tube, string-locking control, and defined stop surfaces that control partial wing exposure and device release. Claims 8 and 9 extend the claimed combination to a hormone-releasing IUD, including a polymeric reservoir containing a contraceptive or menopausal hormone.

The patent issued on July 28, 1998. Its statutory patent term has expired. The claims therefore have no current blocking effect against generic, branded, or device manufacturers in the United States. The patent remains commercially relevant as prior art and as evidence of the technical design history of hormone-releasing IUD inserters, but it does not create present-day exclusivity.

What does U.S. Patent 5,785,053 cover?

The patent covers an inserter system that controls the loading, positioning, partial deployment, and release of an essentially T-shaped IUD.

The core architecture requires:

An elongated plunger with a front end that receives the IUD.
A handle attached to or formed at the rear of the plunger.
A locking device that holds the IUD withdrawal string so the IUD remains stationary relative to the plunger.
A protective tube surrounding the IUD in a contracted configuration.
A first and second stop surface that limit forward movement of the tube.
A deployment position in which the IUD wing tips are partly uncovered but remain pressed together.
Additional stop surfaces that indicate the release position as the protective tube moves toward the handle.

The invention is directed to controlled deployment. It is not limited merely to an IUD inserted through a uterine cavity. The claim requires a particular mechanical relationship among the plunger, protective tube, string lock, and stop surfaces.

What is the claimed technical problem?

A T-shaped IUD must pass through the cervical canal with its transverse arms folded. The inserter must prevent premature opening, control the depth of insertion, and release the IUD at the appropriate point.

The claim addresses those issues by:

retaining the IUD on the plunger through its withdrawal string;
placing the IUD inside a movable protective tube;
limiting forward tube travel before complete wing exposure;
maintaining the wings in a compressed state while the device is positioned;
using a second set of stops to signal or control final release; and
preventing twisting through a concave plunger tip in dependent claim 5.

The patent is therefore a combination patent directed to deployment mechanics rather than to the pharmacological composition of levonorgestrel or another hormone.

How does independent claim 1 define the invention?

Claim 1 is the principal apparatus claim. Its limitations can be grouped into five categories.

Claim element	Required feature	Scope implication
IUD type	Essentially T-shaped IUD with an elongated body and two transverse wings	The claim is directed to a T-shaped or substantially equivalent configuration
Plunger	Front end receives the IUD; rear end has a handle	A free-standing insertion rod without the claimed plunger arrangement may fall outside the claim
String lock	Locking device holds the IUD string so the IUD remains immobile relative to the plunger front end	A system relying only on friction, a separate pusher, or another retention mechanism may avoid literal infringement
Protective tube	Contains the IUD with wings pressed against each other	A device that does not use a surrounding sliding tube may not meet this limitation
Stop surfaces	Tube and plunger stops control partial exposure and release	The relative stop-surface geometry is a central narrowing limitation

The most important limitation is the relationship between the first and second stop surfaces. The protective tube must stop when the wing tips are partly uncovered, while the wings remain pressed together. That positioning requirement distinguishes the claim from a generic sheath that simply retracts until the IUD deploys.

The claim also requires the tube to slide around the plunger and move toward the handle by a distance corresponding substantially to the length of the contracted IUD. A device using a different deployment sequence, such as advancing the IUD through a stationary sheath, presents a stronger noninfringement position.

Which dependent claims add commercial or technical scope?

Claim 2: release-indicating stop surfaces

Claim 2 adds third and fourth stop surfaces. These surfaces abut when the protective tube reaches the point at which it releases the IUD associated with the plunger front end.

This claim narrows claim 1 by requiring two separate stop relationships:

an initial stop controlling partial wing exposure; and
a later stop indicating IUD release.

A competing inserter may avoid claim 2 if it has no distinct release stop, uses a visual depth mark, or relies on a predefined procedural instruction rather than mechanical abutment.

Claim 3: channel-and-knob handle design

Claim 3 requires:

a hollow front end of the handle;
a longitudinal open channel coaxial with the protective tube;
a knob on the protective tube positioned in the channel;
first and third stop surfaces on opposite sides of the knob; and
second and fourth stop surfaces formed by opposite channel surfaces in the handle.

This is the most structurally specific claim. It is likely easier to evaluate through a physical teardown or engineering drawing because the claimed channel, knob, and opposing stop surfaces should be visible or measurable.

A modern inserter with an enclosed handle, radial lock, molded trigger, or unrelated depth-control structure may not satisfy claim 3 even if it performs the same overall clinical function.

Claim 4: hollow plunger for the withdrawal string

Claim 4 requires a hollow bore through which the IUD withdrawal string runs.

This limitation concerns string routing. An inserter with an external string path, side channel, removable string guide, or no string retention in the plunger may fall outside claim 4 while potentially remaining relevant to claim 1.

Claim 5: concave front end

Claim 5 requires a concave plunger front end that catches the tip of the IUD body when the string is tightened, preventing twisting during insertion.

The claim is directed to rotational stability. A flat, convex, forked, cup-shaped, or otherwise differently configured tip would require a detailed equivalence analysis. The concavity must function as a catch for the elongated IUD body tip.

Claim 6: curved forward components

Claim 6 requires the uterine-facing portions of the plunger and protective tube to be curved.

This claim covers curvature in the insertion path. The curvature need not necessarily describe the entire inserter, but the parts directed toward the uterus must be curved. A straight inserter with a flexible distal section may raise a literal-infringement question, depending on the construction of "curved."

Claims 7 to 9: combination with an active IUD

Claim 7 covers the inserter in combination with an IUD.

Claim 8 narrows the IUD to one with:

an elongate member;
a core part; and
a jacket-like polymeric reservoir fitted around the core.

Claim 9 limits the active agent to a hormone used for contraception or treatment of menopausal troubles.

These claims reach beyond a purely mechanical inserter. They cover the combination of the mechanical delivery system with a hormone-reservoir IUD. The language is not limited expressly to levonorgestrel, although the commercial context strongly corresponds to hormone-releasing IUD technology such as the Mirena product family.

How broad is claim 1 under an infringement analysis?

Claim 1 is moderately narrow because it combines multiple structural and functional requirements. A product likely must satisfy each of the following:

T-shaped IUD compatibility;
a plunger that receives the IUD;
a handle;
a string-locking mechanism;
a sliding protective tube;
compressed wings within the tube;
a forward travel limit;
partial exposure of the wing tips at the stop position; and
continued compression of the wings at that position.

The claim is broader than claim 3 because it does not require the specific knob-and-channel handle arrangement. It is narrower than a general claim to an IUD inserter because it requires the specified stop relationship and deployment sequence.

Literal infringement risk

Literal infringement would require each claim limitation to be present in the accused device or system. Key comparison points include:

whether the tube slides around the plunger or the plunger slides within a fixed tube;
whether the string is locked to keep the IUD immobile;
whether the wing tips become partly uncovered before the wings open;
whether a mechanical stop creates that intermediate position;
whether the release event is mechanically indicated by abutting surfaces; and
whether the IUD is held at the plunger front end or released by a separate pusher.

The language "essentially T-shaped" and "substantially" introduces some flexibility, but those terms do not eliminate the structural requirements. A court would likely examine the specification, prosecution history, and ordinary meaning of the terms before deciding how much variation is covered.

Doctrine-of-equivalents risk

The expired status of the patent eliminates current enforcement exposure, but the historic scope remains relevant to prior-art and freedom-to-operate analysis. A substantially different deployment mechanism could have raised a doctrine-of-equivalents issue during the patent term if it performed substantially the same function in substantially the same way to obtain substantially the same result.

The stop-surface limitations would likely have constrained that analysis. Courts generally treat a specifically recited mechanical relationship as more difficult to expand than a purely functional limitation.

When did U.S. Patent 5,785,053 lose exclusivity?

U.S. Patent 5,785,053 has expired under the U.S. patent-term rules. The patent was issued in 1998, and its enforceable term ended no later than the applicable 20-year term measured from the relevant U.S. filing framework, subject to any patent-term adjustment or other recorded term events. The patent is not a current barrier to manufacture or sale.

The patent should be classified as:

Issue	Status
U.S. patent	Expired
Current enforceable exclusion	None
Current Paragraph IV threat	None based solely on this patent
Current Orange Book exclusivity	Not created by this expired inserter patent
Relevance to product design	Historical and prior-art relevance
Relevance to freedom to operate	No current U.S. infringement risk from the expired claims

Patent expiration does not remove the patent from the public record. The claims remain relevant to invalidity analysis, prosecution history, claim construction, and the identification of later patentable improvements.

Is U.S. Patent 5,785,053 listed in the Orange Book?

The patent should not be treated as the source of current Orange Book exclusivity for a hormone-releasing IUD.

The FDA Orange Book primarily records patents and regulatory exclusivity associated with approved drug products. A mechanical inserter patent may be listed only if it satisfies applicable statutory and FDA listing requirements for the approved drug product. A historical device patent is not automatically an Orange Book patent merely because the device is packaged with a drug-containing IUD.

For Mirena and comparable levonorgestrel-releasing IUDs, relevant regulatory and patent analysis must separate:

the levonorgestrel drug component;
the intrauterine delivery system;
the hormone reservoir;
manufacturing processes;
labeling and method-of-use claims; and
the disposable insertion device.

The expiry of Patent 5,785,053 does not establish that all patents associated with a branded hormone-releasing IUD have expired.

What patents protect hormone-releasing IUDs beyond this patent?

The broader patent estate for hormone-releasing IUDs generally divides into five families.

Device and reservoir patents

These patents may cover:

a polymeric drug reservoir around a central core;
a drug-loaded elastomer;
a rate-controlling membrane;
a frame with arms or wings;
radiopaque components;
anchoring structures; and
the relationship between the reservoir and the IUD frame.

Claims 8 and 9 of Patent 5,785,053 address the combination at a high level. They do not necessarily capture every reservoir architecture or every active-agent loading arrangement.

Formulation patents

Formulation claims may cover:

levonorgestrel concentration;
polymer selection;
release-rate control;
reservoir geometry;
stabilizers;
manufacturing conditions; and
long-term drug-release performance.

A formulation patent can remain relevant even after an inserter patent expires because it protects the drug-containing component rather than the deployment instrument.

Method-of-use patents

Method claims may cover:

contraception;
treatment of heavy menstrual bleeding;
treatment of menopausal symptoms;
duration-specific use;
placement in a defined patient population; or
use for a specified therapeutic indication.

A generic or follow-on manufacturer may face a separate analysis for method-of-use patents, particularly where labeling includes protected indications.

Manufacturing patents

Manufacturing claims can cover:

molding or extrusion of the polymer reservoir;
loading of hormone into the polymer;
attachment of the reservoir to the IUD core;
assembly of the frame;
sterilization; and
packaging with the inserter.

These patents can create practical barriers even when the basic product and insertion device are no longer protected.

Inserter improvements

Later patents may claim:

controlled depth markers;
reduced-force insertion;
improved wing folding;
anti-rotation features;
insertion tubes with different deployment sequences;
redesigned string locks; and
packaging or sterilization configurations.

Patent 5,785,053 is therefore one historical layer in a larger product estate, not a complete representation of IUD exclusivity.

What is the relationship to Mirena and competing IUD products?

The claim language corresponds closely to the design requirements of a hormone-releasing T-shaped IUD and its inserter. The commercial landscape includes Bayer's Mirena, Kyleena, and Skyla products, as well as copper IUDs such as ParaGard.

Product category	Active component	Inserter relevance	Patent focus
Hormone-releasing IUD	Levonorgestrel	High	Reservoir, release rate, frame, inserter, use
Copper IUD	Copper	High for mechanical deployment	Frame, copper structure, inserter, use
Generic hormonal IUD	Levonorgestrel or equivalent	High	Product equivalence, formulation, manufacturing, labeling
Generic copper IUD	Copper	High	Device design, materials, manufacturing, regulatory pathway

Patent 5,785,053 is more relevant to the delivery mechanics of a T-shaped IUD than to the identity of the active ingredient. Its claims could theoretically read on an inserter used with a copper or hormonal IUD, subject to the limitations in claims 7 to 9. Claims 8 and 9 narrow the combination to a hormone-reservoir device, but claim 1 itself is not limited to a hormone-containing IUD.

Do biosimilar rules apply to this patent?

No. Biosimilar rules do not apply to the device claims in Patent 5,785,053.

A hormone-releasing IUD is a drug-device combination product, not a biologic. The relevant follow-on pathway depends on the FDA's product classification and approval requirements. A manufacturer may need to address:

abbreviated new drug application requirements;
combination-product requirements;
therapeutic equivalence;
pharmaceutical equivalence;
device performance;
release-rate comparability;
sterilization and biocompatibility; and
labeling differences.

The patent itself does not create a biosimilar issue, and an expired inserter patent cannot block a follow-on product.

Were Paragraph IV challenges or settlements associated with this patent?

An expired mechanical inserter patent does not present a live Paragraph IV challenge opportunity. Paragraph IV litigation concerns a listed patent asserted against an ANDA applicant before patent expiration. Once Patent 5,785,053 expired, a new ANDA applicant would not need to certify that it would market before the patent's expiration.

A historical Paragraph IV dispute could have involved the patent during its term if it was listed for an approved drug product and asserted against an ANDA applicant. The supplied claim text alone does not establish that such litigation occurred. No settlement, license, or court judgment should be attributed to Patent 5,785,053 without a verified docket or licensing record.

The practical conclusion is clear: the patent does not currently generate Paragraph IV launch risk, 30-month-stay risk, or settlement constraints.

What geographic coverage does the patent have?

Patent 5,785,053 provides United States rights only. Foreign equivalents, if any, must be analyzed separately by jurisdiction.

The international landscape may include counterpart applications in:

the European patent system;
Canada;
Australia;
Japan;
Nordic countries; and
other markets where hormone-releasing IUDs were commercialized.

A U.S. expiration finding does not establish that every foreign counterpart expired on the same date. Foreign patents can have different filing dates, prosecution adjustments, maintenance histories, opposition outcomes, and supplementary protection regimes. For U.S. commercial planning, however, the expired status of the U.S. patent removes this patent from the current domestic exclusion analysis.

How strong was the patent estate?

Patent 5,785,053 was technically meaningful but legally narrow in its final claim structure.

Its strengths were:

a concrete mechanical deployment arrangement;
a defined intermediate position for partial wing exposure;
controlled release using stop surfaces;
string-based retention that reduces IUD movement;
dependent claims covering anti-rotation and curved insertion components; and
combination claims directed to hormone-reservoir IUDs.

Its weaknesses were:

dependence on a particular plunger-and-tube architecture;
multiple interacting structural limitations;
potential design-around options using different deployment sequences;
limited coverage of the drug formulation itself; and
expiration of the U.S. patent term.

The claims would have been most valuable against inserters closely copying the claimed stop-surface and sliding-tube arrangement. They would have been less effective against an IUD system using a different retention, release, or wing-deployment mechanism.

What generic launch risks exist today?

Patent 5,785,053 creates no current U.S. generic launch risk because it is expired.

Current risk analysis for a follow-on hormonal IUD should instead examine:

Unexpired patents covering the IUD frame.
Levonorgestrel reservoir composition and release rate.
Manufacturing and assembly methods.
Inserter improvements filed after the 1990s.
Method-of-use claims.
FDA product-specific requirements.
Trade secrets involving manufacturing tolerances and assembly.
Regulatory exclusivity unrelated to the expired patent.
Trademark and trade-dress restrictions.
Product liability and clinical-performance risks.

The expired patent may reduce one historical barrier, but it does not establish that a follow-on IUD can be launched without a full patent and regulatory clearance review.

Key Takeaways

U.S. Patent 5,785,053 covers a controlled inserter for an essentially T-shaped IUD.
Claim 1 requires a plunger, handle, string lock, sliding protective tube, and stop surfaces that maintain partial wing exposure while the wings remain compressed.
Claims 2 and 3 add separate release stops and a specific knob-and-channel handle configuration.
Claims 4 to 6 cover string routing, anti-rotation geometry, and curved forward components.
Claims 7 to 9 extend protection to combinations with hormone-reservoir IUDs.
The patent has expired and does not create current U.S. exclusivity.
It is not a current Paragraph IV or Orange Book barrier.
Biosimilar rules do not apply.
Current freedom-to-operate analysis must focus on later reservoir, formulation, manufacturing, method-of-use, and inserter-improvement patents.
The patent's strongest historical protection was against closely matching mechanical deployment systems.

FAQs

Does Patent 5,785,053 cover Mirena itself?

It covers an inserter and certain inserter-IUD combinations. It does not, by itself, cover every aspect of Mirena, including all levonorgestrel formulation, reservoir, manufacturing, labeling, or therapeutic-use rights.

Can a company manufacture an IUD inserter that resembles the patented design?

Because the U.S. patent has expired, the patent no longer supports an infringement claim. A company must still review later patents, product configuration rights, regulatory requirements, and third-party intellectual property.

Does claim 9 require levonorgestrel?

No. Claim 9 refers generally to a hormone used for contraception or treatment of menopausal troubles. It is not expressly limited to levonorgestrel.

Could claim 1 cover a copper IUD inserter?

Potentially, because claim 1 is not limited to a hormone-containing IUD. It requires the claimed T-shaped IUD and inserter mechanics. Claims 8 and 9, by contrast, require a polymeric hormone-reservoir combination.

Is the patent relevant to a European IUD launch?

Only as a historical reference for the U.S. market. A European launch requires a separate review of national and European counterparts, regulatory approvals, unitary patent rights where applicable, and later patents covering the product or inserter.

Sources

United States Patent and Trademark Office. (1998). U.S. Patent No. 5,785,053, Inserter for an intrauterine device.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (n.d.). Drug-device combination products.
U.S. Food and Drug Administration. (n.d.). Mirena prescribing information.
35 U.S.C. §§ 154, 156, 271, 355.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Finland	945895	Dec 15, 1994

PCT Information
PCT Filed	December 05, 1995	PCT Application Number:	PCT/FI95/00666
PCT Publication Date:	June 20, 1996	PCT Publication Number:	WO96/18365

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	235201	⤷ Start Trial
Australia	4118096	⤷ Start Trial
Australia	693297	⤷ Start Trial
Bulgaria	101744	⤷ Start Trial
Bulgaria	62472	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,785,053